EndoPredict is an mRNA-based multi-gene test for determining the prognosis of breast cancer patients with a hormone receptor-positive, HER2/neu-negative tumour. For analysis the EndoPredict test uses formalin-fixed and paraffin-embedded tissue. The test provides additional information about the tumour, and its result present input for the treatment recommendation of the tumour conference. Many patients could already be spared chemotherapy on the basis of the valid test results.
EndoPredict is a CE-marked product for in vitro diagnostic use.